Lilly plans another study for Alzheimer’s drug

Published



INDIANAPOLIS (AP) — Eli Lilly’s experimental Alzheimer’s drug has flashed potential to help with mild cases of the disease, but patients and doctors will have to wait a few more years to learn whether regulators will allow the drugmaker to sell it.

Lilly said Wednesday that it will launch another late-stage study of the drug, solanezumab, no later than next year’s third quarter. The company’s stock slipped in midday trading.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.